Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at $97.00.
Kostas Biliouris has given his Buy rating due to a combination of factors, including the promising clinical data expected from Crispr Therapeutics AG’s in vivo CRISPR-Cas9 cardiovascular programs. The anticipated announcement of the first clinical data targeting ANGPTL3 and Lp(a) is seen as a significant step, with the efficacy and safety of these programs being partially derisked by existing data from similar technologies. The potential for a positive impact on the stock price, with an expected move of +10-20% based on the readout of CTX310 and CTX320, further supports this rating.
Additionally, the company’s diversified pipeline, including the launch dynamics of Casgevy in 2024 and the development of second-generation allogeneic products like CTX112 and CTX131, adds to the positive outlook. Crispr Therapeutics AG’s rich in vivo pipeline and multiple partnerships provide significant optionality, enhancing the company’s growth prospects. These factors collectively underpin the Outperform rating, reflecting confidence in the company’s strategic direction and potential market impact.